search
Back to results

Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients (NSLEEVE)

Primary Purpose

Severe Obesity, GERD, Bariatric Surgery Candidate

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
N-SLEEVE technique
SLEEVE
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Severe Obesity focused on measuring Obesity, GERD, Surgery

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent form
  • Subjects must be able to attend all scheduled visits and to comply with all trial procedures
  • Subjects must be covered by public health insurance
  • Contraception efficacy
  • Subjects eligible for sleeve gastrectomy after multidisciplinary evaluation according to HAS 2009 criteria: BMI ≥ 40 kg / m² with failure of the dietary treatment for at least 1 year, or a BMI ≥ 35kg / m² with at least one co-morbidity that could be improved after surgery (hypertension, obstructive sleep apnea hypopnea syndrome (OSAHS) and other severe respiratory disorders, severe metabolic disorders (especially type 2 diabetes), debilitating musculoskeletal diseases, non-alcoholic steato-hepatitis (NASH))

Exclusion Criteria:

  • Subject unable to read or/and write
  • Planned longer stay outside the region that prevents compliance with the visit plan
  • Current pregnancy
  • Previous bariatric surgery (ring, vertical banded gastroplasty, sleeve gastrectomy or Gastric Bypass).
  • BMI > 50 kg / m² for women and > 45kg / m² for men (dissecting the hiatus region can be a technical challenge in these cases).
  • Barrett oesophagus and esophagitis stage III and IV.
  • Funditis
  • Long-term NSAIDs and/or corticosteroid therapy
  • No affiliation at the French social security scheme.
  • Major protected by law.
  • Deprivation of liberty by judicial or administrative decision.
  • Participation to another clinical research program.

Sites / Locations

  • CHU Montpellier

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

N SLEEVE

SLEEVE

Arm Description

Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).

The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.

Outcomes

Primary Outcome Measures

Presence of gastroesophageal reflux disease
Gastroscopy is a standard endoscopic examination that examines the lining of the oesophagus and stomach. It can detect Helicobacter pylori and highlight the presence of: Gastro-Oesophageal Reflux Disease Gastritis Esophagitis Barrett's oesophagus Hiatal hernia Gastric tumor Bile reflux Incompetent cardia
Consumption of Proton Pump Inhibitor
The consumption of PPI, revealing the presence of GERD symptoms, will be recorded at each visit thanks a diary card.

Secondary Outcome Measures

type of fistula Month 1
The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
severity of fistula Month 1
The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
type of fistula Month 6
The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
severity of fistula Month 6
The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
type of fistula Month 12
The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
severity of fistula Month 12
The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
Postoperative morbidity Month 1
Assessed by the type of postoperative complication
Postoperative morbidity Month 6
Assessed by the frequency of each type of postoperative complication
Postoperative morbidity Month 12
Assessed by the severity of each type of postoperative complication
Weight loss Month 1
The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
Weight loss Month 6
The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
Weight loss Month 12
The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
mortality Month 1
number of death
mortality Month 6
number of death
mortality Month 12
number of death
Quality of Life Month 1 : SF 12
Quality of life will be assessed by the self-questionnaire SF12
Quality of Life Month 6 : SF 12
Quality of life will be assessed by the self-questionnaire SF12
Quality of Life Month 12 : SF 12
Quality of life will be assessed by the self-questionnaire SF12
Serious adverse event Month 1
number and type of adverse events
safety Month 6: number and type of adverse events
number and type of adverse events
safety Month 12: number and type of adverse events
number and type of adverse events

Full Information

First Posted
October 8, 2020
Last Updated
November 10, 2020
Sponsor
University Hospital, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT04626232
Brief Title
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
Acronym
NSLEEVE
Official Title
Monocentric Prospective Randomized Controlled Study Comparing the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique (N-Sleeve) in Morbidly Obese Patients
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 5, 2021 (Anticipated)
Primary Completion Date
July 5, 2023 (Anticipated)
Study Completion Date
July 5, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the impact of the procedure (sleeve gastrectomy technique with a Nissen fundoplication (N-Sleeve) vs conventional sleeve gastrectomy technique
Detailed Description
Bariatric surgery is recognized as the only effective therapeutic weapon for morbidly obese patients. Gastro-Oesophageal Reflux Disease is very common (30-45% of cases) with serious consequences on the oesophageal mucosa. It could be an exacerbation of preoperative GERD symptoms or a "de novo" postoperative GERD. Medical treatment is usually effective but reoperation may be required to treat refractory GERD.GERD can lead to serious consequences on the oesophageal mucosa (esophagitis, Barrett's oesophagus, cancer). The conventional surgical treatment of GERD is fundoplication, which can be partial or total. The gastric fundus is wrapped around the oesophagus to strengthen the tone of the oesophageal sphincter. We hypothesize that the creation of a total anti-reflux fundoplication before performing LSG (Nissen + Sleeve = N-sleeve) could significantly reduce the postoperative GERD complication as compared with the standard LSG. To evaluate the impact of the procedure N-Sleeve vs conventional sleeve gastrectomy technique on the rate of patient with GERD at 1, 6 and 12 months postoperatively. To evaluate the impact of the procedure (sleeve gastrectomy technique with a Nissen fundoplication (N-Sleeve) vs conventional sleeve gastrectomy technique during all the follow-up on the gastric fistula on the staple line, on the postoperative morbidity and mortality , on the evolution of weight loss, the excess weight loss, the BMI and the excess BMI loss during the follow-up. Evaluate the impact of these procedures on the quality of life of patients at baseline and 1, 6 and 12 months postoperatively. Evaluate the safety during all the follow-up. •Methods: Monocentric, randomized, single-blind controlled trial, with 2 parallel arms. 144 patients. The target population is all adult patients with severe or morbid obesity, who underwent multidisciplinary care and having the criteria of 2009 HAS recommendations for bariatric surgery. Presence of gastro-oesophageal reflux will be assessed by a composite criteria: consumption of Proton Pump Inhibitor and gastroscopy at baseline and 12-month. The N-SLEEVE technique consists of creating a gastric total fundoplication before to perform the removal of 2/3 of the stomach. This study may really lead to a change in terms of choice of first intention bariatric procedures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Obesity, GERD, Bariatric Surgery Candidate, Morbid Obesity
Keywords
Obesity, GERD, Surgery

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
144 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
N SLEEVE
Arm Type
Experimental
Arm Description
Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
Arm Title
SLEEVE
Arm Type
Other
Arm Description
The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
Intervention Type
Procedure
Intervention Name(s)
N-SLEEVE technique
Intervention Description
The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
Intervention Type
Procedure
Intervention Name(s)
SLEEVE
Intervention Description
SLEEVE Technique : Removal of 2/3 of the stomach
Primary Outcome Measure Information:
Title
Presence of gastroesophageal reflux disease
Description
Gastroscopy is a standard endoscopic examination that examines the lining of the oesophagus and stomach. It can detect Helicobacter pylori and highlight the presence of: Gastro-Oesophageal Reflux Disease Gastritis Esophagitis Barrett's oesophagus Hiatal hernia Gastric tumor Bile reflux Incompetent cardia
Time Frame
12 months
Title
Consumption of Proton Pump Inhibitor
Description
The consumption of PPI, revealing the presence of GERD symptoms, will be recorded at each visit thanks a diary card.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
type of fistula Month 1
Description
The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
Time Frame
Month 1
Title
severity of fistula Month 1
Description
The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
Time Frame
Month 1
Title
type of fistula Month 6
Description
The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
Time Frame
Month 6
Title
severity of fistula Month 6
Description
The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
Time Frame
Month 6
Title
type of fistula Month 12
Description
The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
Time Frame
Month 12
Title
severity of fistula Month 12
Description
The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
Time Frame
Month 12
Title
Postoperative morbidity Month 1
Description
Assessed by the type of postoperative complication
Time Frame
Month 1
Title
Postoperative morbidity Month 6
Description
Assessed by the frequency of each type of postoperative complication
Time Frame
Month 6
Title
Postoperative morbidity Month 12
Description
Assessed by the severity of each type of postoperative complication
Time Frame
Month 12
Title
Weight loss Month 1
Description
The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
Time Frame
Month 1
Title
Weight loss Month 6
Description
The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
Time Frame
Month 6
Title
Weight loss Month 12
Description
The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
Time Frame
Month 12
Title
mortality Month 1
Description
number of death
Time Frame
Month 1
Title
mortality Month 6
Description
number of death
Time Frame
Month 6
Title
mortality Month 12
Description
number of death
Time Frame
Month 12
Title
Quality of Life Month 1 : SF 12
Description
Quality of life will be assessed by the self-questionnaire SF12
Time Frame
Month 1
Title
Quality of Life Month 6 : SF 12
Description
Quality of life will be assessed by the self-questionnaire SF12
Time Frame
Month 6
Title
Quality of Life Month 12 : SF 12
Description
Quality of life will be assessed by the self-questionnaire SF12
Time Frame
Month 12
Title
Serious adverse event Month 1
Description
number and type of adverse events
Time Frame
Month 1
Title
safety Month 6: number and type of adverse events
Description
number and type of adverse events
Time Frame
Month 6
Title
safety Month 12: number and type of adverse events
Description
number and type of adverse events
Time Frame
Month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent form Subjects must be able to attend all scheduled visits and to comply with all trial procedures Subjects must be covered by public health insurance Contraception efficacy Subjects eligible for sleeve gastrectomy after multidisciplinary evaluation according to HAS 2009 criteria: BMI ≥ 40 kg / m² with failure of the dietary treatment for at least 1 year, or a BMI ≥ 35kg / m² with at least one co-morbidity that could be improved after surgery (hypertension, obstructive sleep apnea hypopnea syndrome (OSAHS) and other severe respiratory disorders, severe metabolic disorders (especially type 2 diabetes), debilitating musculoskeletal diseases, non-alcoholic steato-hepatitis (NASH)) Exclusion Criteria: Subject unable to read or/and write Planned longer stay outside the region that prevents compliance with the visit plan Current pregnancy Previous bariatric surgery (ring, vertical banded gastroplasty, sleeve gastrectomy or Gastric Bypass). BMI > 50 kg / m² for women and > 45kg / m² for men (dissecting the hiatus region can be a technical challenge in these cases). Barrett oesophagus and esophagitis stage III and IV. Funditis Long-term NSAIDs and/or corticosteroid therapy No affiliation at the French social security scheme. Major protected by law. Deprivation of liberty by judicial or administrative decision. Participation to another clinical research program.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marta SILVESTRI, MedD
Phone
+33 7.83.76.13.22
Email
m-silvestri@chu-montpellier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Guillemette TACONNET, PharmD
Phone
+33 4.67.33.55.73
Email
g-taconnet_decker@chu-montpellier.fr
Facility Information:
Facility Name
CHU Montpellier
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marta SILVESTRI, MedD
Phone
+ 33 7.83.76.13.22
Email
m-silvestri@chu-montpellier.fr
First Name & Middle Initial & Last Name & Degree
Guillemette TACONNET, PharmD
Phone
+ 33 4.67.33.55.73
Email
g-taconnet_decker@chu-montpellier.fr

12. IPD Sharing Statement

Learn more about this trial

Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients

We'll reach out to this number within 24 hrs